The impact of sequential chemoradiotherapy versus concurrent chemoradiotherapy on prognosis in adjuvant treatment after radical hysterectomy for cervical cancer

This study aimed to compare the efficacy and toxicity of sequential chemoradiotherapy (SCRT) versus concurrent chemoradiotherapy (CCRT) in patients receiving adjuvant treatment after radical hysterectomy for cervical cancer. A retrospective analysis was conducted on 236 patients who underwent radical hysterectomy for cervical cancer in our gynecology, oncology, and radiotherapy departments from February 2018 to January 2022. Patients were divided into two groups based on their postoperative adjuvant treatment: the SCRT group (n = 112) and the CCRT group (n = 124). Follow-up evaluations were conducted over a period of 3 years. Patient data, including demographic characteristics, cancer characteristics, efficacy, toxicity assessment, and survival outcomes, were collected through the medical record system. Significant differences were noted in grade 3–4 treatment-related toxicities, with CCRT showing higher rates of leucopenia (P = 0.003) and nausea/vomiting (P = 0.003). In terms of survival outcomes, while overall survival rates were similar between the two groups, the CCRT group demonstrated significantly better progression-free survival (PFS) (34.89 ± 3.76 months vs. 33.58 ± 5.42 months, P = 0.033) compared to the SCRT group. CCRT is associated with better PFS but also higher rates of severe leucopenia and nausea/vomiting. Multivariate analysis identified CCRT (Hazard Ratio [HR] = 0.522), well-differentiated tumor grading (HR = 0.535), early-stage disease (FIGO stage I) (HR = 0.322), and better performance status (ECOG score of 0) (HR = 0.266) as independent protective factors against shorter PFS (P < 0.05). In the adjuvant treatment after radical hysterectomy for cervical cancer, CCRT is associated with better PFS but also higher rates of severe leucopenia and nausea/vomiting. CCRT may offer a therapeutic advantage in delaying disease progression and extending survival times, despite its increased toxicity.

Authors

Institutions

Publication Details

Journal
World Journal of Surgical Oncology
Published
2025-12-17
DOI
https://doi.org/10.1186/s12957-025-04149-7
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The impact of sequential chemoradiotherapy versus concurrent chemoradiotherapy on prognosis in adjuvant treatment after radical hysterectomy for cervical cancer

Shaodong Shi, Yuhong Ma
World Journal of Surgical Oncology
Endometrial and Cervical Cancer Treatments
article

The impact of sequential chemoradiotherapy versus concurrent chemoradiotherapy on prognosis in adjuvant treatment after radical hysterectomy for cervical cancer

Shaodong Shi, Yuhong Ma
article en

Abstract

This study aimed to compare the efficacy and toxicity of sequential chemoradiotherapy (SCRT) versus concurrent chemoradiotherapy (CCRT) in patients receiving adjuvant treatment after radical hysterectomy for cervical cancer. A retrospective analysis was conducted on 236 patients who underwent radical hysterectomy for cervical cancer in our gynecology, oncology, and radiotherapy departments from February 2018 to January 2022. Patients were divided into two groups based on their postoperative adjuvant treatment: the SCRT group (n = 112) and the CCRT group (n = 124). Follow-up evaluations were conducted over a period of 3 years. Patient data, including demographic characteristics, cancer characteristics, efficacy, toxicity assessment, and survival outcomes, were collected through the medical record system. Significant differences were noted in grade 3–4 treatment-related toxicities, with CCRT showing higher rates of leucopenia (P = 0.003) and nausea/vomiting (P = 0.003). In terms of survival outcomes, while overall survival rates were similar between the two groups, the CCRT group demonstrated significantly better progression-free survival (PFS) (34.89 ± 3.76 months vs. 33.58 ± 5.42 months, P = 0.033) compared to the SCRT group. CCRT is associated with better PFS but also higher rates of severe leucopenia and nausea/vomiting. Multivariate analysis identified CCRT (Hazard Ratio [HR] = 0.522), well-differentiated tumor grading (HR = 0.535), early-stage disease (FIGO stage I) (HR = 0.322), and better performance status (ECOG score of 0) (HR = 0.266) as independent protective factors against shorter PFS (P < 0.05). In the adjuvant treatment after radical hysterectomy for cervical cancer, CCRT is associated with better PFS but also higher rates of severe leucopenia and nausea/vomiting. CCRT may offer a therapeutic advantage in delaying disease progression and extending survival times, despite its increased toxicity.

World Journal of Surgical OncologyVol. 24(1)
Shanxi Medical University (CN), Changzhi Medical College (CN), Shanxi Provincial People’s Hospital (CN)
Openalex Percentile: Top 48%
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.